{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:36:36Z","timestamp":1741754196000,"version":"3.38.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10754-4","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:05:42Z","timestamp":1741698342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Eric Kasongo","family":"Mukenge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blaise Matondo-Manzambi","family":"Sumbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliocha Natuhoyila","family":"Nkodila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremie Masidi","family":"Muwonga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Robert Rissassi","family":"Makulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamy Zita","family":"Ngole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben Izizag","family":"Bepouka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murielle Mashi","family":"Longokolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guyguy","family":"Kamwiziku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hippolyte Nanituma","family":"Situakibanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie Ntumba","family":"Kayembe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Longo-Mbenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George Lelo","family":"Mvumbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baudouin","family":"Buassa-Bu-Tsumbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Claude","family":"Makangara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9sire Kulimba","family":"Mashinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Musalu","family":"Mafuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatien Sonzi","family":"Mangala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille Nganga","family":"Nkanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustave Ntita","family":"Ilunga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fonce Tshibawu","family":"Nkunda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Nsimba","family":"Lengo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve Mundeke","family":"Ahuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"10754_CR1","doi-asserted-by":"publisher","unstructured":"Changing epidemiology of COVID-19 : potential future impact on vaccines andvaccination strategies. Expert Rev Vaccines 2024;23(1):510-522.\u00a0https:\/\/doi.org\/10.1080\/14760584.","DOI":"10.1080\/14760584"},{"issue":"9","key":"10754_CR2","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year ofCOVID-19 vaccination\u202f: a mathematical modelling study. Lancet InfectDis. 2022;22(9):1293\u2013302.","journal-title":"Lancet InfectDis"},{"issue":"194","key":"10754_CR3","doi-asserted-by":"publisher","first-page":"E297","DOI":"10.1503\/cmaj.211881-f","volume":"28","author":"K Yau","year":"2022","unstructured":"Yau K, Chan CT, Kento TA, Yidi J, Atiquzzaman M, Mullin SI, et al. Diff\u00e9rences d\u2019immunog\u00e9nicit\u00e9 des vaccins anti SRAS-CoV-2 mRNA-1273 (Moderna) et BNT162b2 (Pfizer-BioNTech) chez les patients dialys\u00e9s. CMAJ. 2022;28(194):E297-305. https:\/\/doi.org\/10.1503\/cmaj.211881-f.","journal-title":"CMAJ"},{"key":"10754_CR4","doi-asserted-by":"publisher","unstructured":"Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv 2021. https:\/\/doi.org\/10.1101\/2021.08.06.21261707.","DOI":"10.1101\/2021.08.06.21261707"},{"key":"10754_CR5","unstructured":"Ritchie H, Ortiz-Ospina E, Beltekian D, et al. Coronavirus Pandemic (COVID-19). Our World in Data. Published online March 5, 2020. https:\/\/ourworldindata.org\/coronavirus. Accessed 12 Sep 2024."},{"issue":"8","key":"10754_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.medj.2021.06.007","volume":"2","author":"C Pawlowski","year":"2021","unstructured":"Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan AJ, Niesen MJM, et al. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med. 2021;2(8):979-992.e8. https:\/\/doi.org\/10.1016\/j.medj.2021.06.007.","journal-title":"Med"},{"issue":"10","key":"10754_CR7","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.vaccine.2021.12.046","volume":"40","author":"SJ Thomas","year":"2022","unstructured":"Thomas SJ, Perez JL, Lockhart SP, Hariharan S, Kitchin N, Bailey R, et al. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine. 2022;40(10):1483\u201392.","journal-title":"Vaccine"},{"issue":"19","key":"10754_CR8","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824\u201335.","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10754_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","journal-title":"N Engl J Med"},{"key":"10754_CR10","unstructured":"COVID-19 Cumulative Infection Collaborators. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14,. a statistical analysis. Lancet. 2021;2022(399):2351\u201380."},{"key":"10754_CR11","unstructured":"Monin-Aldama L, Laing AG, Mu\u00f1oz-Ruiz M, McKenzie DR, del Molino del Barrio I, Alaguthurai T, et al. Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines. Oncology. 2021. Disponible sur :\u00a0http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.03.17.21253131."},{"issue":"34","key":"10754_CR12","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1016\/j.vaccine.2022.06.077","volume":"40","author":"AL Barrall","year":"2022","unstructured":"Barrall AL, Hoff NA, Nkamba DM, Musene K, Ida N, Anna Bratcher A, et al. Hesitancy to receive the novel coronavirus vaccine and potential influences on vaccination among a cohort of healthcare workers in the Democratic Republic of the Congo. Vaccine. 2022;40(34):4998\u20135009.","journal-title":"Vaccine"},{"key":"10754_CR13","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1038\/s41467-021-24979-9","volume":"12","author":"N Ortega","year":"2021","unstructured":"Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S, et al. Sevenmonth kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat Commun. 2021;12:4740.","journal-title":"Nat Commun"},{"key":"10754_CR14","doi-asserted-by":"publisher","unstructured":"Nash D, Srivastava A, Shen Y, Penrose K, Kulkarni SG, Zimba R et al. Seroincidence of SARS\u2011CoV\u20112 infection prior to and during the rollout of vaccines in a community\u2011based prospective cohort of U.S. adults. Sci Rep. 2024;14:644. https:\/\/doi.org\/10.1038\/s41598-023-51029-9.","DOI":"10.1038\/s41598-023-51029-9"},{"key":"10754_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12879-023-08728-5","volume":"23","author":"SW Yoon","year":"2023","unstructured":"Yoon SW, Widyasari K, Jang J, Lee S, Kang T, Kim S. Kinetics of adaptive immune responses after administering mRNA-Based COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infections. BMC Infect Dis. 2023;23:732. https:\/\/doi.org\/10.1186\/s12879-023-08728-5.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10754_CR16","doi-asserted-by":"publisher","first-page":"100971","DOI":"10.1016\/j.xcrm.2023.100971","volume":"4","author":"FJ Ryan","year":"2023","unstructured":"Ryan FJ, Norton TS, McCafferty C, Blake SJ, Stevens NE, James J. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. Cell Rep Med. 2023;4(3):100971. https:\/\/doi.org\/10.1016\/j.xcrm.2023.100971.","journal-title":"Cell Rep Med"},{"key":"10754_CR17","doi-asserted-by":"publisher","unstructured":"Addo IY, Dadzie FA, Okeke SR, Boadi C, Boadu EF. Duration of immunity following full vaccination against SARSCoV-2: a systematic review. Arch Public Health 2022;80:200. https:\/\/doi.org\/10.1186\/s13690-022-00935-x.","DOI":"10.1186\/s13690-022-00935-x"},{"key":"10754_CR18","doi-asserted-by":"publisher","unstructured":"Dadras O,\u00a0SeyedAlinaghi S,\u00a0Karimi A,\u00a0Shojaei A,\u00a0Amiri A, Mahdiabadi S. COVID-19 vaccines\u2019 protection over time and the need for booster doses; a systematic review. Arch Acad Emergency Med. 2022;10(1):e53. https:\/\/doi.org\/10.22037\/aaem.v10i1.1582.","DOI":"10.22037\/aaem.v10i1.1582"},{"key":"10754_CR19","doi-asserted-by":"publisher","unstructured":"Shrotri M,\u00a0Navaratnam A,\u00a0Nguyen V,\u00a0Byrne T,\u00a0Geismar C,\u00a0Fragaszy E et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398:385\u2013387. https:\/\/doi.org\/10.1016\/S0140-6736(21)01642-1.","DOI":"10.1016\/S0140-6736(21)01642-1"},{"key":"10754_CR20","doi-asserted-by":"publisher","unstructured":"Choi JH,\u00a0Kim YR,\u00a0Heo ST,\u00a0Oh H,\u00a0Kim M,\u00a0Lee HR et al. Healthcare workers in south korea maintain a SARS-CoV-2 antibody response 6 months after receiving a second dose of the BNT162b2 mRNA vaccine. Front Immunol. 2022;13:827306. https:\/\/doi.org\/10.3389\/fimmu.2022.827306.","DOI":"10.3389\/fimmu.2022.827306"},{"key":"10754_CR21","doi-asserted-by":"publisher","unstructured":"Hosseinian S,\u00a0Powers K,\u00a0Vasudev M,\u00a0Palma AM,\u00a0Rafael de Assis,\u00a0Jain A et al. Persistence of SARS-CoV-2 antibodies in vaccinated health care workers analyzed by coronavirus antigen microarray. Front Immunol. 2022;13:817345. https:\/\/doi.org\/10.3389\/fimmu.2022.817345.","DOI":"10.3389\/fimmu.2022.817345"},{"key":"10754_CR22","doi-asserted-by":"publisher","unstructured":"Berry AA,\u00a0Tjaden AH,\u00a0Renteria J,\u00a0Klabanoff DF,\u00a0Hinkelman AN,\u00a0Gibbs AM. Persistence of antibody responses to COVID-19 vaccines among participants in the COVID-19 community research partnership. Vaccine X. 2023;15:100371. https:\/\/doi.org\/10.1016\/j.jvacx.","DOI":"10.1016\/j.jvacx"},{"key":"10754_CR23","doi-asserted-by":"publisher","unstructured":"Chen Y,\u00a0Yin S,\u00a0Tong X,\u00a0Tao Y,\u00a0Ni J,\u00a0Pan J et al. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Clin Microbiol Infect. 2022;28:410\u2013418. https:\/\/doi.org\/10.1016\/j.cmi.2021.10.006.","DOI":"10.1016\/j.cmi.2021.10.006"},{"key":"10754_CR24","doi-asserted-by":"publisher","unstructured":"Kwok SL, Cheng SM, Leung JN, Leung K, Lee CK, Peiris JSM et al. Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021. Euro Surveill.\u00a02022;27(2):2101197. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.2.2101197.","DOI":"10.2807\/1560-7917.ES.2022.27.2.2101197"},{"key":"10754_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.trsl.2021.10.004","volume":"240","author":"C Dobano","year":"2022","unstructured":"Dobano C, Jimenez A, Rubio R, Alonso S, Ramirez-Morros A, Vidal M, et al. Spike-based COVID-19 immunization increases antibodies to nucleocapsid antigen. Transl Res. 2022;240:26\u201332.","journal-title":"Transl Res"},{"key":"10754_CR26","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","volume":"398","author":"APS Munro","year":"2021","unstructured":"Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258\u201376.","journal-title":"Lancet"},{"key":"10754_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.it.2020.04.001","volume":"41","author":"JS Tsang","year":"2020","unstructured":"Tsang JS, Doba\u00f1o C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving vaccine-induced immunity: can baseline predict outcome? Trends Immunol. 2020;41:457\u201365.","journal-title":"Trends Immunol"},{"key":"10754_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41467-021-27649-y","volume":"13","author":"N Koerber","year":"2022","unstructured":"Koerber N, Priller A, Yazici S, Bauer T, Cheng C-C, Mijo\u010devi\u0107 H, et al. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nat Commun. 2022;13:153.","journal-title":"Nat Commun"},{"issue":"6","key":"10754_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/10408363.2022.2038539","volume":"59","author":"KI Notarte","year":"2022","unstructured":"Notarte KI, Ver AT, Velasco JV, Pastrana A, Catahay JA, Salvagno GL, et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci. 2022;59(6):373\u201390.","journal-title":"Crit Rev Clin Lab Sci."},{"key":"10754_CR30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41467-022-28527-x","volume":"13","author":"H Ward","year":"2022","unstructured":"Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A, et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13:907.","journal-title":"Nat Commun"},{"key":"10754_CR31","doi-asserted-by":"publisher","unstructured":"Zintel S, Flock C, Arbogast AL, Forster A,\u00a0Wagner CV, Sieverding M. Gender differences in\u00a0the\u00a0intention to\u00a0get vaccinated against\u00a0COVID-19: a\u00a0systematic review and\u00a0meta-analysis. J Public Health. 2022;1\u201310.\u00a0https:\/\/doi.org\/10.1007\/s10389-021-01677-w.","DOI":"10.1007\/s10389-021-01677-w"},{"issue":"10345","key":"10754_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0140-6736(22)01189-8","volume":"400","author":"T Nassiri-Ansari","year":"2022","unstructured":"Nassiri-Ansari T, Atuhebwe P, Sika Ayisi A, Goulding S, Johri M, Allotey P, et al. Shifting gender barriers in immunisation in the COVID-19 pandemic response and beyond. The Lancet. 2022;400(10345):24.","journal-title":"The Lancet"},{"key":"10754_CR33","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.3390\/jcm10235498","volume":"10","author":"H Naruse","year":"2021","unstructured":"Naruse H, Ito H, Izawa H, Sarai M, Ishii J, Sakaguchi E, et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease. J Clin Med. 2021;10:5498.","journal-title":"J Clin Med"},{"key":"10754_CR34","doi-asserted-by":"publisher","first-page":"779212","DOI":"10.3389\/fimmu.2021.779212","volume":"12","author":"SW Lee","year":"2021","unstructured":"Lee SW, Moon J-Y, Lee S-K, Lee H, Moon S, Chung SJ, et al. Anti-SARSCoV- 2 Spike protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19 (AZD1222) vaccine in healthcare workers: lack of association with age, sex, obesity, and adverse reactions. Front Immunol. 2021;12:779212.","journal-title":"Front Immunol"},{"key":"10754_CR35","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S2213-2600(21)00407-0","volume":"9","author":"G Milne","year":"2021","unstructured":"Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, et al. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Lancet Respir Med. 2021;9:1450\u201366.","journal-title":"Lancet Respir Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10754-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:05:48Z","timestamp":1741698348000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10754-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10754"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10754-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all the participants and\/or their legally acceptable representatives. Non-literate participants were accompanied by a literate peer of their choice. Participants under 18\u00a0years of age were accompanied by their parent or guardian. Their informed assents and consent from parent or guardian were requested and signed before the enrolment to the study. Participants had the right to provide consent or not and to withdraw from the study at any time during the interview, without having to provide a reason. The risks incurred by the participants in this study were supposed to be minimal, given that the vaccines used had already undergone clinical trials and been approved by scientists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"342"}}